Next Article in Journal
Interactions between a Heparin Trisaccharide Library and FGF-1 Analyzed by NMR Methods
Next Article in Special Issue
New Insights in Thyroid Cancer and p53 Family Proteins
Previous Article in Journal
Age-Related Changes in Immunological and Physiological Responses Following Pulmonary Challenge
Previous Article in Special Issue
Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(6), 1292; doi:10.3390/ijms18061292

Differentiated Thyroid Cancer—Treatment: State of the Art

Department of Nuclear Medicine, University of Regensburg, 93053 Regensburg, Germany
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 6 April 2017 / Revised: 5 June 2017 / Accepted: 5 June 2017 / Published: 17 June 2017
(This article belongs to the Special Issue Current Knowledge in Thyroid Cancer—From Bench to Bedside)
View Full-Text   |   Download PDF [617 KB, uploaded 19 June 2017]   |  

Abstract

Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence has increased over the last few decades. It derives from follicular thyroid cells. Generally speaking, the prognosis is excellent. If treatment according to the current guidelines is given, cases of recurrence or persistence are rare. DTC requires special expertise by the treating physician. In recent years, new therapeutic options for these patients have become available. For this article we performed a systematic literature review with special focus on the guidelines of the American Thyroid Association, the European Association of Nuclear Medicine, and the German Society of Nuclear Medicine. For DTC, surgery and radioiodine therapy followed by levothyroxine substitution remain the established therapeutic procedures. Even metastasized tumors can be cured this way. However, in rare cases of radioiodine-refractory tumors, additional options are to be discussed. These include strict suppression of thyroid-stimulating hormone (also known as thyrotropin, TSH) and external local radiotherapy. Systemic cytostatic chemotherapy does not play a significant role. Recently, multikinase or tyrosine kinase inhibitors have been approved for the treatment of radioiodine-refractory DTC. Although a benefit for overall survival has not been shown yet, these new drugs can slow down tumor progression. However, they are frequently associated with severe side effects and should be reserved for patients with threatening symptoms only. View Full-Text
Keywords: differentiated thyroid cancer; radioiodine therapy; targeted therapy; tyrosine kinase inhibitors differentiated thyroid cancer; radioiodine therapy; targeted therapy; tyrosine kinase inhibitors
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Schmidbauer, B.; Menhart, K.; Hellwig, D.; Grosse, J. Differentiated Thyroid Cancer—Treatment: State of the Art. Int. J. Mol. Sci. 2017, 18, 1292.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top